The introduction of Intel’s (NASDAQ:INTC) newest artificial intelligence chip, Gaudi 3, is projected to benefit three global semiconductor companies significantly. What Happened: According to Morgan Stanley, TSMC (NYSE:TSM), Alchip (OTC:ALCPF) and Wistron (OTC:WICOF) stand to gain the most from the demand for Intel’s latest AI chip, CNBC reported on Tuesday. The financial institution anticipates that Intel’s supply issues will be resolved in the second half of 2024, leading to a surge in confirmed sales. TSMC will be responsible for the fabrication of Gaudi 3 chips using its latest-generation 5-nanometer process. Alchip is expected to provide design services for both Gaudi 2 and Gaudi 3, while Wistron is predicted to be the primary baseboard supplier. Charlie Chan and his team at Morgan Stanley forecast that the total Gaudi shipment volume could hit 300-400k units in 2025, generating $2-3bn revenue for Intel. The investment bank also reiterated its overweight rating on Alchip and TSMC, considering ...Full story available on Benzinga.com

The introduction of Intel’s (NASDAQ:INTC) newest artificial intelligence chip, Gaudi 3, is projected to benefit three global semiconductor companies significantly. What Happened: According to Morgan Stanley, TSMC (NYSE:TSM), Alchip (OTC:ALCPF) and Wistron (OTC:WICOF) stand to gain the most from the demand for Intel’s latest AI chip, CNBC reported on Tuesday. The financial institution anticipates that Intel’s supply issues will be resolved in the second half of 2024, leading to a surge in confirmed sales. TSMC will be responsible for the fabrication of Gaudi 3 chips using its latest-generation 5-nanometer process. Alchip is expected to provide design services for both Gaudi 2 and Gaudi 3, while Wistron is predicted to be the primary baseboard supplier. Charlie Chan and his team at Morgan Stanley forecast that the total Gaudi shipment volume could hit 300-400k units in 2025, generating $2-3bn revenue for Intel. The investment bank also reiterated its overweight rating on Alchip and TSMC, considering ...Full story available on Benzinga.com

DENVER, CO, April 23, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Ubiquitech Software Corp. (OTC: UBQU), a trailblazer in innovative software development, is pleased to announce that during its fiscal second quarter, an additional $700,000 of convertible debt principal and accrued interest has been eliminated from the corporate balance sheet.  This brings the total convertible debt reduction over the past twelve months to over $1,700,000. The final numbers will be reflected in the company’s financial statements filed with OTCMarkets.com on or before July 15, 2024.

Leading electric vehicle company Tesla Inc (NASDAQ:TSLA) reports first-quarter financial results after market close Tuesday, April 23. Here are the key earnings estimates, what analysts are saying and key items to watch. Earnings Estimates: Analysts expect Tesla to report first-quarter revenue of $22.34 billion, according to data from Benzinga Pro. The company reported revenue of $23.33 billion in last year's first quarter. Tesla has beaten revenue estimates from analysts in three of the last five quarters. Analysts expect Tesla to report earnings per share of 51 cents in the first quarter, compared to 85 cents reported in last year's first quarter. Over the past five quarters, Tesla beat analysts' earnings per share two times, missed two times and was even one time. Tesla missed revenue and earnings per share estimates in the past two quarters compared to estimates from analysts. In its fourth-quarter financial results, the company said it was between growth waves. "In 2024, our vehicle growth rate may be notably lower than the growth rate achieved in 2023," the company said. Related Link: Tesla Q4 Earnings Highlights: Revenue Miss, EPS Miss, Model Y A Global Bestseller, Next-Gen Vehicle Update And More What Analysts Are Saying: Tesla had several well-known issues that would factor into the first quarter earnings results, Bank of America analyst John Murphy said in a new investor note. "TSLA stock has been under material pressure due to both weaker EV fundamentals and sentiment around the electrification theme," Murphy said. The analyst had a Neutral rating and price target of $220 on Tesla. Murphy said the focus from investors would be on demand and future growth plans from Tesla. "Despite near-term ...Full story available on Benzinga.com

BofA Securities analyst Justin Post reiterated a Buy rating on Meta Platforms Inc (NASDAQ:META) with a price target of $550. The analyst marginally increased his first-quarter estimates for positive ad checks and Easter benefits but lowered second-quarter and 2024 estimates for recent U.S. dollar depreciation.  Post estimates first-quarter revenue of $36.4 billion (up 27% Y/Y) above Street at $36.2 billion.  Also Read: Google’s DeepMind to Lead Unified AI Charge as Company Seeks to Outpace Microsoft He expects ad revenue to grow 26% year over year to $35.5 billion (vs. the Street at $35.4 billion), with 2 points of Q/Q acceleration.  Post estimates EBITDA at $20.9 billion and EPS at $4.48, above Street at $20.3 billion and $4.33, respectively.  For users, Sensor Tower suggests healthy Instagram users & time spent (though Facebook time ...Full story available on Benzinga.com

Stocks surged higher on Thursday, with the S&P 500 index aiming to snap a four-day losing streak as investors assess the latest wave of corporate earnings. During midday trading in New York, all major indices were in the green. Notably, small caps, as tracked by the iShares Russell 2000 ETF (NYSE:IWM), outperformed, posting a 1% increase. Industry-wise, airline stocks continued their upward momentum, with the U.S. Global Jets ETF (NYSE:JETS) climbing 2.7%, building on Wednesday’s 3.9% surge. Tesla Inc. (NASDAQ:TSLA) had another lackluster session, declining over 3% and on track for its lowest close since January 2023. This decline followed Deutsche Bank’s downgrade of the EV-maker from Buy to Hold, citing concerns over the strategic pivot to autonomous vehicles. On the data front, the Philadelphia Fed Manufacturing Index posted ...Full story available on Benzinga.com

Johnson & Johnson (NYSE: JNJ) reported better-than-expected first-quarter earnings on Tuesday. The company posted adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64. The pharma giant reported sales of $21.38 billion, up 2.3% year over year, almost in line with the consensus of $21.39 billion, according to data from Benzinga Pro. Johnson & Johnson also raised its quarterly dividend by 4.2% from $1.19 per share to $1.24 per share. Johnson & Johnson said it expects fiscal year 2024 operational sales of $88.7 billion-$89.1 billion versus prior guidance ...Full story available on Benzinga.com

Monday, in an interim analysis of Marinus Pharmaceuticals Inc’s (NASDAQ:MRNS) phase 3 RAISE trial, evaluating intravenous (IV) ganaxolone as a treatment for refractory status epilepticus (RSE), failed to meet pre-defined “stopping criteria.” Marinus has completed RAISE enrollment at approximately 100 patients, with topline results expected in the summer of 2024. The company said the future development of IV ganaxolone in refractory status epilepticus will be assessed following a review of the final RAISE study results. An independent Data Monitoring Committee (DMC) recommended continuing the study. Cantor Fitzgerald said it shifted focus to oral ganaxolone (O-GNX), which is progressing in the global Phase 3 TrustTSC study for tuberous ...Full story available on Benzinga.com

Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc (NASDAQ:AVTX), noting that its AVTX-009 is a promising drug candidate and looks forward to a Phase 2 topline data in 2026 in hidradenitis suppurativa (HS) and additional updates. In March, Avalo Therapeutics announced the acquisition of a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, originally developed by Eli Lilly And Co (NYSE:LLY). Avalo announced a private placement of $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million. Oppenheimer says that the company is preparing to advance ‘009 for Phase 2 development in hidradenitis suppurativa (HS), showing confidence in its potential. While topline data won’t be available until 2026, there’s consideration to also ...Full story available on Benzinga.com

Leading streaming company Netflix Inc (NASDAQ:NFLX) is set to report first-quarter financial earnings on April 18. An analyst sizes up expectations for Netflix's upcoming report. The Netflix Analyst: Piper Sandler analyst Matt Farrell has a Neutral rating. Farrell also raised the price target from $550 to $600. Related Link: Netflix Revamps Film Division with Genre-Specific Focus Under New Leadership The Analyst Takeaways: After a strong fourth quarter from Netflix, expectations are elevated for the streaming giant in the first quarter, Farrell said. Sentiment for Netflix went from "better than feared" in the third quarter to "how big is the beat" now, after the fourth-quarter report, he added. "We believe investors are looking for material upside to the 4.5 million net adds number for Q1," Farrell said. Netflix reported 13.12 million net ...Full story available on Benzinga.com

Across the recent three months, 4 analysts have shared their insights on Performance Food Gr (NYSE:PFGC), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 3 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $82.75, a high estimate of $86.00, and a low estimate of $80.00. This current average reflects an increase of 7.12% from the previous average price target of $77.25. Interpreting Analyst Ratings: A Closer Look The perception of Performance Food Gr by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Brian Harbour Morgan Stanley Raises Equal-Weight $80.00 $78.00 Jeffrey Bernstein Barclays Raises Overweight $86.00 $78.00 Kelly Bania BMO Capital Raises Outperform $80.00 $78.00 Joshua Long Stephens & Co. Raises Overweight $85.00 $75.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Performance Food Gr. This information provides a snapshot of how analysts perceive ...Full story available on Benzinga.com

Friday, Agenus Inc (NASDAQ:AGEN) released updated results from its Phase 1 clinical trial of botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic colorectal cancer (CRC) that is not microsatellite instability-high (MSS) or deficient mismatch repair (dMMR).  These findings build upon the compelling clinical activity demonstrated by BOT/BAL across nine different cancer types in Agenus’ broad clinical development program. In the Phase 1 trial of 77 patients with refractory MSS-CRC without active liver metastases, a 23% overall response rate (ORR) was observed after a median follow up of 13.6 months at the data cutoff of March 1, 2024.  The median duration of response in 18 responders has not yet been reached. The estimated 12-month and 18-month overall survival (OS) rates were 71% and 62%, respectively. The median OS was 21.2 months. The Phase 2 trial has completed enrollment and the ...Full story available on Benzinga.com

In the preceding three months, 4 analysts have released ratings for Edgewell Personal Care (NYSE:EPC), presenting a wide array of perspectives from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 1 1 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $38.5, along with a high estimate of $43.00 and a low estimate of $35.00. This current average reflects an increase of 4.05% from the previous average price target of $37.00. Analyzing Analyst Ratings: A Detailed Breakdown The analysis of recent analyst actions sheds light on the perception of Edgewell Personal Care by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Lauren Lieberman Barclays Lowers Equal-Weight $37.00 $39.00 Chris Carey Wells Fargo Raises Overweight $43.00 $40.00 Lauren Lieberman Barclays Announces Equal-Weight $39.00 - Lauren Lieberman Barclays Raises Underweight $35.00 $32.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Edgewell Personal Care. ...Full story available on Benzinga.com

Toast (NYSE:TOST) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 7 2 0 Last 30D 0 0 0 1 0 1M Ago 1 0 3 0 0 2M Ago 0 2 3 1 0 3M Ago 1 0 1 0 0 Analysts have recently evaluated Toast and provided 12-month price targets. The average target is $22.85, accompanied by a high estimate of $32.00 and a low estimate of $15.00. Observing a 36.74% increase, the current average has risen from the previous average price target of $16.71. Investigating Analyst Ratings: An Elaborate Study The perception of Toast by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Jeff Cantwell Wells Fargo Raises Underweight $17.00 $15.00 Daniel Perlin RBC Capital Maintains Sector Perform $23.00 - Sanjay Sakhrani Keefe, Bruyette & Woods Announces Market Perform $25.00 - Timothy Chiodo UBS Raises Buy $31.00 $22.00 Dan Dolev Mizuho Maintains Neutral $17.00 $17.00 Thomas Poutrieux Exane BNP Paribas Announces Outperform $30.00 - Sheriq Sumar Evercore ISI Group Announces Outperform $32.00 - Dan Dolev Mizuho Raises Neutral $17.00 $14.00 Jeff Cantwell Wells Fargo Raises Underweight $15.00 $12.00 Daniel Perlin RBC Capital Raises Sector Perform $23.00 $19.00 Clarke Jeffries Piper Sandler Raises Neutral $20.00 $18.00 Dominic Ball Redburn Atlantic Announces Buy $28.00 - Daniel Perlin RBC Capital Announces Sector Perform $19.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their ...Full story available on Benzinga.com

Ratings for US Foods Hldg (NYSE:USFD) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 1 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 1 0 0 2M Ago 2 2 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $59.14, a high estimate of $64.00, and a low estimate of $52.00. This upward trend is evident, with the current average reflecting a 16.28% increase from the previous average price target of $50.86. Breaking Down Analyst Ratings: A Detailed Examination The perception of US Foods Hldg by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Brian Harbour Morgan Stanley Raises Overweight $62.00 $60.00 Peter Saleh BTIG Raises Buy $62.00 $52.00 John Ivankoe JP Morgan Raises Neutral $52.00 $50.00 Mark Carden UBS Raises Buy $64.00 $47.00 Nicole Miller Regan Piper Sandler Raises Overweight $59.00 $45.00 Jake Bartlett Truist Securities Raises Buy $57.00 $52.00 Kelly Bania BMO Capital Raises Outperform $58.00 $50.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction ...Full story available on Benzinga.com

During the last three months, 4 analysts shared their evaluations of Hain Celestial Group (NASDAQ:HAIN), revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 1 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.5, a high estimate of $10.00, and a low estimate of $8.00. This current average has decreased by 13.64% from the previous average price target of $11.00. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Hain Celestial Group by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Andrew Lazar Barclays Lowers Equal-Weight $8.00 $11.00 John Baumgartner Mizuho Lowers Neutral $10.00 $11.00 Brian Holland DA Davidson Announces Neutral $10.00 - Ken Goldman JP Morgan Lowers Neutral $10.00 $11.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hain Celestial Group. This information provides a snapshot of how analysts perceive the current state ...Full story available on Benzinga.com

BMO Capital Markets analyst Keith Bachman reiterated the Outperform rating on Microsoft Corporation (NASDAQ:MSFT), raising the forecast to $465 from $455. Per the analyst, Microsoft’s valuation is reasonable on an EV/FCF and P/E basis, but not inexpensive.  The analyst writes that AI can help support longer-term growth, and the durable growth opportunities warrant a premium valuation. Microsoft is well positioned in the gaming market, particularly since leading content and scale are sources of competitive advantage. In the December quarter, gaming generated 11% of total revenues. While ...Full story available on Benzinga.com

RBC Capital analyst Rishi Jaluria reiterated Salesforce Inc (NYSE:CRM) with an Outperform and raised the price target from $325 to $350. The analyst hosted investor meetings with Valmik Desai, Director of Investor Relations, and Brooke Bakewell, Senior Manager of Investor Relations, which focused on Generative Artificial Intelligence, Data Cloud, margins, and macro. Jaluria noted that customers are enthusiastic about generative AI and, in many cases, are turning to Salesforce to help with their AI strategies.  Also Read: Salesforce Spends $20M on Einstein Image Rights, Securing AI Brand Dominance and Guinness Record That said, with Copilot in public beta and no release date set yet, it will likely take time before GenAI conversations translate into meaningful revenue (fiscal 2025 guidance assumes no GenAI contribution).  The analyst noted that the company believes it is well-positioned to benefit from AI because Salesforce, especially Sales/Service Cloud, serves as a control plane where people spend the vast majority of their day and a store for the majority of customer-centric data.  Salesforce’s first signs of ...Full story available on Benzinga.com

Keybanc analyst Justin Patterson maintained Spotify Technology SA (NYSE:SPOT) with an Overweight rating and raised the price target from $300 to $350. Spotify will report its first-quarter fiscal 2024 results before the market opens on April 23. Patterson refined his estimates and framed vital factors to watch.  The analyst now expects 2024 revenue of €15.4 billion and 2025 revenue of €18.0 billion, which reflects slightly higher ARPU growth. His 2024 operating profit decreases by 20% due to social charges, while 2025 increases by 2% due to higher revenue.  Finally, Patterson introduced 2026 revenue of €20.6 billion and an operating profit of €2.2 billion, which assumes 14% revenue growth, 29.9% ...Full story available on Benzinga.com

BlackRock, Inc. (NYSE:BLK) shares are trading lower on Friday. The company reported revenue growth of 11% year over year to $4.728 billion in the first quarter, beating the consensus of $4.676 billion.  According to Goldman Sachs analyst Alexander Blostein, the company’s management fees of $3.778 billion missed consensus by 1% on worse-than-expected fee rate dynamics.  Blostein writes equity fee rates were light across all product types, and the Alts fee rate declined three bps quarter on quarter as catch-up fees rolled off, and Tech/risk management fees were also a bit light (-1% versus Street). The analyst adds that flows were driven by ...Full story available on Benzinga.com

Mizuho analyst John Roberts upgraded the shares of Ecolab Inc (NYSE:ECL) from Neutral to Buy and raised the price target from $216 to $260. According to the analyst, ECL appears back to its historical beat-and-raise visibility. The analyst noted that the company had almost 25 years of meeting or exceeding quarterly consensus estimates before the pandemic. Meanwhile, the analyst added that ECL is not resilient against travel/hospitality collapses, which happened during the pandemic & immediately post-9/11.  Greater cleanliness protects customer ...Full story available on Benzinga.com

Ratings for Western Digital (NASDAQ:WDC) were provided by 20 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 11 5 0 0 Last 30D 0 0 1 0 0 1M Ago 2 3 1 0 0 2M Ago 0 1 2 0 0 3M Ago 2 7 1 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $74.5, a high estimate of $115.00, and a low estimate of $58.00. Observing a 25.61% increase, the current average has risen from the previous average price target of $59.31. Decoding Analyst Ratings: A Detailed Look The standing of Western Digital among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Toshiya Hari Goldman Sachs Raises Neutral $76.00 $58.00 Aaron Rakers Wells Fargo Raises Overweight $95.00 $72.00 Medhi Hosseini Susquehanna Raises Neutral $83.00 $68.00 Vijay Rakesh Mizuho Raises Buy $80.00 $66.00 C J Muse Cantor Fitzgerald Raises Overweight $100.00 $70.00 Kevin Cassidy Rosenblatt Raises Buy $115.00 $65.00 Amit Daryanani Evercore ISI Group Announces Outperform $80.00 - C J Muse Cantor Fitzgerald Maintains Overweight $70.00 - Timothy Arcuri UBS Raises Neutral $65.00 $55.00 Kevin Cassidy Rosenblatt Raises Neutral $65.00 $60.00 Toshiya Hari Goldman Sachs Raises Neutral $58.00 $48.00 Vijay Rakesh Mizuho Raises Buy $66.00 $62.00 Tom O'Malley Barclays Raises Overweight $70.00 $65.00 C J Muse Cantor Fitzgerald Maintains Overweight $70.00 - Aaron Rakers Wells Fargo Raises Overweight $72.00 $62.00 Srini Pajjuri Raymond James Raises Outperform $65.00 $60.00 C J Muse Cantor Fitzgerald Announces Overweight $70.00 - Srini Pajjuri Raymond James Raises Outperform $60.00 $48.00 Tom O'Malley Barclays Raises Overweight $65.00 $45.00 Sidney Ho Deutsche Bank Raises Buy $65.00 $45.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and ...Full story available on Benzinga.com

Science Applications Intl (NASDAQ:SAIC) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 3 0 1 Last 30D 0 0 1 0 0 1M Ago 0 0 2 0 0 2M Ago 0 0 0 0 1 3M Ago 0 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $130.75, a high estimate of $143.00, and a low estimate of $110.00. Observing a downward trend, the current average is 0.95% lower than the prior average price target of $132.00. Interpreting Analyst Ratings: A Closer Look The analysis of recent analyst actions sheds light on the perception of Science Applications Intl by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Tobey Sommer Truist Securities Maintains Hold $130.00 - Seth Seifman JP Morgan Lowers Neutral $140.00 $142.00 Matthew Akers Wells Fargo Raises Equal-Weight $143.00 $141.00 Gavin Parsons Goldman Sachs Lowers Sell $110.00 $113.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects ...Full story available on Benzinga.com

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Federated Hermes (NYSE:FHI) in the last three months. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 1 2 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $39.0, a high estimate of $44.00, and a low estimate of $36.00. Observing a 4.84% increase, the current average has risen from the previous average price target of $37.20. Breaking Down Analyst Ratings: A Detailed Examination The standing of Federated Hermes among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Adam Beatty UBS Raises Neutral $39.00 $37.00 John Dunn Evercore ISI Group Raises Outperform $39.00 $36.00 Kenneth Lee RBC Capital Raises Sector Perform $37.00 $36.00 Kenneth Lee RBC Capital Raises Sector Perform $36.00 $34.00 Kenneth Worthington JP Morgan Raises Overweight $44.00 $43.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent ...Full story available on Benzinga.com

8 analysts have expressed a variety of opinions on Inari Medical (NASDAQ:NARI) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 3 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 1 0 0 2M Ago 3 0 2 0 0 3M Ago 1 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $66.75, along with a high estimate of $75.00 and a low estimate of $52.00. This current average has decreased by 8.06% from the previous average price target of $72.60. Investigating Analyst Ratings: An Elaborate Study The perception of Inari Medical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target William Plovanic Canaccord Genuity Maintains Buy $75.00 $75.00 Richard Newitter Truist Securities Lowers Hold $52.00 $61.00 Mike Matson Needham Maintains Buy $72.00 - Mike Matson Needham Maintains Buy $72.00 - Richard Newitter Truist Securities Lowers Hold $61.00 $63.00 Adam Maeder Piper Sandler Lowers Neutral $55.00 $85.00 William Plovanic Canaccord Genuity Lowers Buy $75.00 $79.00 Mike Matson Needham Announces Buy $72.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Inari Medical. This information provides ...Full story available on Benzinga.com

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Tenet Healthcare (NYSE:THC) in the last three months. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 8 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 3 0 0 0 2M Ago 1 3 0 0 0 3M Ago 2 2 0 0 0 Analysts have recently evaluated Tenet Healthcare and provided 12-month price targets. The average target is $109.75, accompanied by a high estimate of $126.00 and a low estimate of $100.00. Marking an increase of 13.14%, the current average surpasses the previous average price target of $97.00. Analyzing Analyst Ratings: A Detailed Breakdown The standing of Tenet Healthcare among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Pito Chickering Deutsche Bank Raises Buy $126.00 $100.00 Sarah James Cantor Fitzgerald Maintains Overweight $104.00 - Stephen Baxter Wells Fargo Raises Overweight $115.00 $105.00 Justin Lake Wolfe Research Announces Outperform $122.00 - Ann Hynes Mizuho Raises Buy $110.00 $100.00 Andrew Mok Barclays Announces Overweight $113.00 - Sarah James Cantor Fitzgerald Maintains Overweight $104.00 - Stephen Baxter Wells Fargo Raises Overweight $105.00 $98.00 David Macdonald Truist Securities Raises Buy $105.00 $92.00 Ben Hendrix RBC Capital Raises Outperform $109.00 $97.00 Ann Hynes Mizuho Raises Buy $100.00 $90.00 Sarah James Cantor Fitzgerald Raises Overweight $104.00 $94.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving ...Full story available on Benzinga.com

Vertex Pharmaceuticals (NASDAQ:VRTX) underwent analysis by 16 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 8 2 0 2 Last 30D 0 0 0 0 1 1M Ago 1 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 3 6 2 0 1 Analysts have set 12-month price targets for Vertex Pharmaceuticals, revealing an average target of $453.25, a high estimate of $559.00, and a low estimate of $371.00. This current average has increased by 7.58% from the previous average price target of $421.31. Deciphering Analyst Ratings: An In-Depth Analysis The analysis of recent analyst actions sheds light on the perception of Vertex Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Whitney Ijem Canaccord Genuity Maintains Sell $371.00 $371.00 Andrew Fein HC Wainwright & Co. Raises Buy $462.00 $457.00 Liisa Bayko Evercore ISI Group Announces Outperform $438.00 - Olivia Brayer Cantor Fitzgerald Maintains Overweight $440.00 - Olivia Brayer Cantor Fitzgerald Maintains Overweight $440.00 - Jessica Fye JP Morgan Raises Overweight $450.00 $438.00 Mohit Bansal Wells Fargo Raises Overweight $540.00 $500.00 Brian Abrahams RBC Capital Raises Sector Perform $420.00 $397.00 Gena Wang Barclays Raises Overweight $472.00 $446.00 Liisa Bayko Evercore ISI Group Raises In-Line $438.00 $436.00 Andrew Fein HC Wainwright & Co. Raises Buy $457.00 $397.00 Jessica Fye JP Morgan Raises Overweight $438.00 $390.00 Robyn Karnauskas Truist Securities Raises Buy $508.00 $456.00 Salveen Richter Goldman Sachs Raises Buy $559.00 $442.00 Olivia Brayer Cantor Fitzgerald Raises Overweight $440.00 $415.00 Whitney Ijem Canaccord Genuity Raises Sell $379.00 $332.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' ...Full story available on Benzinga.com

Technology giant Apple Inc (NASDAQ:AAPL) is set to report second-quarter financial results after market close on May 2, 2024, with investors and analysts ready to hear more about several catalysts, including question marks over demand in China. A leading analyst previewed the second quarter earnings with several catalysts that could lead to a strong second half of fiscal 2024. The Apple Analyst: Goldman Sachs analyst Michael Ng had a Buy rating on Apple and lowered the price target from $232 to $226. Related Link: Apple Q1 Earnings Beat Estimates As Cupertino Snaps 4-Quarter Revenue Decline Streak; Stock Slides On China Weakness The Analyst Takeaways: Second-quarter iPhone revenue could decline 11% year-over-year to $45.9 billion, according to estimates from the analyst. "The overall industry environment for smartphones and PCS is improving, which should be supportive for AAPL product sales in C2024/25 (calendar years 2024, 2025)," Ng ...Full story available on Benzinga.com

Needham analyst Quinn Bolton reiterated a Buy rating on Marvell Technology Inc (NASDAQ:MRVL) with a price target of $95. On Thursday, Marvell hosted its Accelerated Infrastructure for the AI Era Event, at which it laid out its Data Center expectations and growth drivers. Growth opportunities include custom computing, cloud optics, AEC DSPs, silicon photonics (SiPho), and Ethernet switching.  Marvell’s key announcements included the company’s third North American hyperscaler customer for custom silicon, likely to generate more revenue than its first two hyperscaler customers combined, expectations for AI revenue to exceed $1.5 billion and $2.5 billion in fiscal 2025 and fiscal 2026, respectively, and an updated Data Center TAM that will exceed $75 billion in 2028 with Marvell’s goal to secure 20% share of this TAM long-term. Also Read: Marvell Technology Poised To Expand Leadership In AI Chip Market, Analyst Sees Market Potential Worth Billions Should the company achieve ...Full story available on Benzinga.com

Ratings for FS KKR Capital (NYSE:FSK) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 6 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 4 0 0 3M Ago 0 0 1 0 0 Analysts have set 12-month price targets for FS KKR Capital, revealing an average target of $19.5, a high estimate of $20.00, and a low estimate of $18.00. A decline of 2.5% from the prior average price target is evident in the current average. Breaking Down Analyst Ratings: A Detailed Examination A clear picture of FS KKR Capital's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Melissa Wedel JP Morgan Raises Neutral $19.00 $18.00 Kenneth Lee RBC Capital Lowers Sector Perform $20.00 $21.00 Mark Hughes Truist Securities Lowers Hold $20.00 $22.00 Richard Shane JP Morgan Lowers Neutral $18.00 $20.00 Erik Zwick Hovde Group Announces Market Perform $20.00 - Timothy O'Shea Wells Fargo Raises Equal-Weight $20.00 $19.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to FS KKR Capital. This information provides a snapshot ...Full story available on Benzinga.com

Analysts' ratings for Regenxbio (NASDAQ:RGNX) over the last quarter vary from bullish to bearish, as provided by 9 analysts. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 4 2 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 4 2 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $38.22, a high estimate of $55.00, and a low estimate of $21.00. This current average has increased by 1.25% from the previous average price target of $37.75. Deciphering Analyst Ratings: An In-Depth Analysis In examining recent analyst actions, we gain insights into how financial experts perceive Regenxbio. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Annabel Samimy Stifel Maintains Buy $40.00 - Yi Chen HC Wainwright & Co. Announces Buy $36.00 - Luca Issi RBC Capital Raises Outperform $35.00 $20.00 Daniil Gataulin Chardan Capital Maintains Buy $52.00 $52.00 Gena Wang Barclays Raises Overweight $55.00 $45.00 Brian Skorney Baird Raises Outperform $39.00 $34.00 Andreas Argyrides Wedbush Maintains Neutral $21.00 - Dane Leone Raymond James Announces Outperform $45.00 - Andreas Argyrides Wedbush Maintains Neutral $21.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects ...Full story available on Benzinga.com

7 analysts have expressed a variety of opinions on Deere (NYSE:DE) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 3 0 0 Last 30D 0 0 1 0 0 1M Ago 1 0 0 0 0 2M Ago 2 1 2 0 0 3M Ago 0 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $427.43, a high estimate of $494.00, and a low estimate of $387.00. Witnessing a positive shift, the current average has risen by 0.53% from the previous average price target of $425.17. Analyzing Analyst Ratings: A Detailed Breakdown The standing of Deere among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Tami Zakaria JP Morgan Raises Neutral $425.00 $415.00 Jamie Cook Truist Securities Announces Buy $494.00 - David Raso Evercore ISI Group Raises In-Line $387.00 $381.00 Nicole Deblase Deutsche Bank Lowers Hold $401.00 $425.00 Seth Weber Wells Fargo Lowers Overweight $425.00 $445.00 Timothy Thein Citigroup Lowers Buy $435.00 $450.00 Stanley Elliott Stifel Lowers Buy $425.00 $435.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to ...Full story available on Benzinga.com

During the last three months, 4 analysts shared their evaluations of Blackstone Secured (NYSE:BXSL), revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 0 1 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $31.25, a high estimate of $32.00, and a low estimate of $30.50. This current average reflects an increase of 5.5% from the previous average price target of $29.62. Decoding Analyst Ratings: A Detailed Look The standing of Blackstone Secured among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Melissa Wedel JP Morgan Raises Overweight $31.50 $30.00 Arren Cyganovich Citigroup Raises Buy $31.00 $30.00 Mark Hughes Truist Securities Raises Buy $32.00 $30.00 Timothy O'Shea Wells Fargo Raises Overweight $30.50 $28.50 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blackstone Secured. This information provides a snapshot of how analysts ...Full story available on Benzinga.com

Throughout the last three months, 4 analysts have evaluated Oaktree Specialty Lending (NASDAQ:OCSL), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Oaktree Specialty Lending, presenting an average target of $20.88, a high estimate of $22.00, and a low estimate of $20.00. Highlighting a 0.57% decrease, the current average has fallen from the previous average price target of $21.00. Investigating Analyst Ratings: An Elaborate Study The perception of Oaktree Specialty Lending by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Melissa Wedel JP Morgan Lowers Overweight $20.00 $21.00 Kevin Mcveigh JMP Securities Maintains Market Outperform $21.00 - Timothy O'Shea Wells Fargo Lowers Overweight $20.50 $22.00 Timothy O'Shea Wells Fargo Raises Overweight $22.00 $20.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Oaktree Specialty Lending. This offers insight into analysts' perspectives on the current state of the company. Rating: Analyzing trends, analysts ...Full story available on Benzinga.com

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Reynolds Consumer Prods (NASDAQ:REYN) in the last three months. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 5 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 2 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 2 0 0 Analysts have recently evaluated Reynolds Consumer Prods and provided 12-month price targets. The average target is $29.2, accompanied by a high estimate of $31.00 and a low estimate of $27.00. This current average reflects an increase of 8.15% from the previous average price target of $27.00. Decoding Analyst Ratings: A Detailed Look The standing of Reynolds Consumer Prods among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Lauren Lieberman Barclays Raises Equal-Weight $28.00 $27.00 Mark Astrachan Stifel Maintains Hold $30.00 - Nik Modi RBC Capital Maintains Sector Perform $31.00 - Andrea Teixeira JP Morgan Raises Neutral $30.00 $29.00 Lauren Lieberman Barclays Raises Equal-Weight $27.00 $25.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Reynolds Consumer Prods. This offers ...Full story available on Benzinga.com

As the retail landscape evolves amidst changing consumer behaviors and economic shifts, investors seek guidance on navigating this dynamic sector. The JPMorgan Retail Round-Up Conference 2024 shed light on key themes shaping the retail landscape this year, including: Stable U.S. consumer backdrop Resurgence in denim and activewear categories Renewed focus on consumer value. Amidst these trends, Christopher Horvers, head of U.S. Broadlines and Hardlines Retail at JPMorgan, presented compelling stock picks poised for growth in the retail sector. 1. Wayfair: Offers Upside From Sales, Margins Horvers expressed optimism about Wayfair Inc (NYSE:W), the leading online specialty retailer. He attributed its potential for growth to the improving demand for home goods. With sales expected to rise alongside the resurgence in home-related purchases, Wayfair stood to benefit from its dominance in the online home furnishings category. Horvers noted the company’s focus on cost optimization post-Covid-19 pandemic. “We see upside not only from sales but also from margins,” said Hoervers. 2. Lowe’s: Outdoor Patio Demand To See Acute Uplift Horvers ...Full story available on Benzinga.com

Shares of CarMax Inc (NYSE: KMX) were falling in early trading on Friday, after the company reported downbeat earnings for its fiscal fourth quarter. The results came amid an exciting earnings season. Here are some key analyst takeaways from the release. Needham On CarMax Analyst Chris Pierce reiterated a Buy rating, while reducing the price target from $99 to $91. Hopes of an industry recovery have been pushed out due to expectations of Federal Reserve delays interest rate cuts, “putting the burden of growth on share gains,” Pierce said in a note. CarMax gained share in three of the five months, starting in October, the analyst stated. “A linear path to share gains would clearly be preferable, but we ...Full story available on Benzinga.com

In recent evaluations by Zuanic & Associates and Water Tower Research LLC, Gold Flora Corporation (OTC: GRAM), a key player in the competitive California cannabis market, reported its financial outcomes for the fourth quarter of 2023. Despite a strategic decision leading to an 11% sequential dip in revenue, dropping to $28.4 million, the company’s focus on closing non-viable delivery depots and divesting an underperforming retail license has favorably impacted its profitability. Adjusted gross profit surged by 11.60% quarter-over-quarter to $18.7 million, and adjusted EBITDA turned a positive corner at $105,000, improving from a negative $459,000 in the previous quarter. Although the company made less money this period, dropping to $28.4 million, its profits rose to $18.7 million, and it earned more money than it spent, making $105,000 compared to losing $459,000 in the previous quarter. Interested in the latest developments in the industry? Stay abreast at the upcoming Benzinga Cannabis Capital Conference in Florida on April 16-17. The two-day event at The Diplomat Beach Resort is a chance for entrepreneurs, both large and small, to network, learn, and grow. Get your tickets now on bzcannabis.com – Prices will ...Full story available on Benzinga.com

In the preceding three months, 4 analysts have released ratings for Plains GP Holdings (NASDAQ:PAGP), presenting a wide array of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 1 1 1 Last 30D 0 0 0 1 1 1M Ago 0 1 0 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.62, a high estimate of $23.00, and a low estimate of $16.00. This upward trend is apparent, with the current average reflecting a 18.83% increase from the previous average price target of $15.67. Investigating Analyst Ratings: An Elaborate Study The standing of Plains GP Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Theresa Chen Barclays Raises Underweight $18.00 $16.00 John Mackay Goldman Sachs Raises Sell $16.00 $14.50 Tristan Richardson Scotiabank Announces Sector Outperform $23.00 - Spiro Dounis Citigroup Raises Neutral $17.50 $16.50 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Plains GP Holdings. This information offers a snapshot ...Full story available on Benzinga.com

25 analysts have shared their evaluations of Salesforce (NYSE:CRM) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 9 10 6 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 8 7 6 0 0 3M Ago 0 2 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $330.72, a high estimate of $360.00, and a low estimate of $285.00. This current average reflects an increase of 10.52% from the previous average price target of $299.23. Investigating Analyst Ratings: An Elaborate Study The standing of Salesforce among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Rishi Jaluria RBC Capital Raises Outperform $350.00 $325.00 Parker Lane Stifel Maintains Buy $350.00 - Tyler Radke Citigroup Raises Neutral $339.00 $325.00 David Hynes Canaccord Genuity Maintains Buy $350.00 $350.00 Joseph Bonner Argus Research Raises Buy $354.00 $290.00 Patrick Walravens JMP Securities Raises Market Outperform $342.00 $293.00 Kirk Materne Evercore ISI Group Raises Outperform $330.00 $290.00 Rishi Jaluria RBC Capital Raises Outperform $325.00 $285.00 Mark Murphy JP Morgan Raises Overweight $310.00 $260.00 Brad Sills B of A Securities Raises Buy $360.00 $350.00 Gregg Moskowitz Mizuho Raises Buy $345.00 $325.00 David Hynes Canaccord Genuity Raises Buy $350.00 $290.00 Terry Tillman Truist Securities Raises Buy $360.00 $275.00 Keith Bachman BMO Capital Raises Outperform $335.00 $325.00 Scott Berg Needham Raises Buy $345.00 $275.00 Rob Oliver Baird Raises Outperform $355.00 $310.00 Brent Bracelin Piper Sandler Raises Neutral $300.00 $285.00 Brent Bracelin Piper Sandler Maintains Neutral $285.00 - Tyler Radke Citigroup Raises Neutral $325.00 $265.00 Michael Turrin Wells Fargo Raises Equal-Weight $290.00 $280.00 Parker Lane Stifel Raises Buy $330.00 $300.00 Karl Keirstead UBS Raises Neutral $310.00 $285.00 Brian Schwartz Oppenheimer Raises Outperform $325.00 $300.00 Rob Oliver Baird Raises Outperform $310.00 $300.00 Patrick Walravens JMP Securities Maintains Market Outperform $293.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it ...Full story available on Benzinga.com

In the latest quarter, 14 analysts provided ratings for Church & Dwight Co (NYSE:CHD), showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 4 4 0 Last 30D 0 0 0 1 0 1M Ago 0 0 0 0 0 2M Ago 3 1 0 0 0 3M Ago 1 1 4 3 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $100.64, along with a high estimate of $115.00 and a low estimate of $76.00. This upward trend is apparent, with the current average reflecting a 7.33% increase from the previous average price target of $93.77. Exploring Analyst Ratings: An In-Depth Overview The analysis of recent analyst actions sheds light on the perception of Church & Dwight Co by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Lauren Lieberman Barclays Raises Underweight $83.00 $80.00 Dara Mohsenian Morgan Stanley Raises Overweight $114.00 $109.00 Bonnie Herzog Goldman Sachs Raises Buy $110.00 $91.00 Bonnie Herzog Goldman Sachs Maintains Buy $110.00 $110.00 Taylor Conrad Argus Research Announces Buy $115.00 - Bill Chappell Truist Securities Raises Buy $110.00 $105.00 Mark Astrachan Stifel Raises Hold $99.00 $91.00 Lauren Lieberman Barclays Raises Underweight $80.00 $76.00 Mark Astrachan Stifel Raises Hold $99.00 $91.00 Peter Grom UBS Raises Neutral $105.00 $99.00 Nik Modi RBC Capital Raises Sector Perform $103.00 $94.00 Rupesh Parikh Oppenheimer Raises Outperform $110.00 $107.00 Andrea Teixeira JP Morgan Raises Underweight $95.00 $87.00 Lauren Lieberman Barclays Lowers Underweight $76.00 $79.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Church & Dwight Co. This information offers a snapshot of how analysts perceive the current state of the ...Full story available on Benzinga.com

Plains All American (NASDAQ:PAA) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 1 0 1 Last 30D 0 0 0 0 1 1M Ago 1 1 0 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.88, along with a high estimate of $23.00 and a low estimate of $16.00. Surpassing the previous average price target of $17.33, the current average has increased by 14.71%. Investigating Analyst Ratings: An Elaborate Study An in-depth analysis of recent analyst actions unveils how financial experts perceive Plains All American. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target John Mackay Goldman Sachs Raises Sell $16.00 $14.50 Tristan Richardson Scotiabank Announces Sector Outperform $23.00 - Neal Dingmann Truist Securities Raises Buy $23.00 $21.00 Spiro Dounis Citigroup Raises Neutral $17.50 $16.50 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to ...Full story available on Benzinga.com

4 analysts have expressed a variety of opinions on Talos Energy (NYSE:TALO) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Talos Energy, presenting an average target of $18.38, a high estimate of $20.00, and a low estimate of $16.50. Highlighting a 14.51% decrease, the current average has fallen from the previous average price target of $21.50. Diving into Analyst Ratings: An In-Depth Exploration A clear picture of Talos Energy's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Subash Chandra Benchmark Maintains Buy $20.00 - Paul Diamond Citigroup Announces Buy $16.50 - Derrick Whitfield Stifel Lowers Buy $17.00 $20.00 Subash Chandra Benchmark Lowers Buy $20.00 $23.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it ...Full story available on Benzinga.com

During the last three months, 4 analysts shared their evaluations of Brookfield (NYSE:BN), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 2 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $52.0, a high estimate of $53.00, and a low estimate of $50.00. Witnessing a positive shift, the current average has risen by 4.69% from the previous average price target of $49.67. Breaking Down Analyst Ratings: A Detailed Examination The analysis of recent analyst actions sheds light on the perception of Brookfield by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Geoffrey Kwan RBC Capital Maintains Outperform $53.00 - Geoffrey Kwan RBC Capital Raises Outperform $53.00 $52.00 Mario Saric Scotiabank Raises Sector Outperform $50.00 $49.00 Kenneth Worthington JP Morgan Raises Overweight $52.00 $48.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' ...Full story available on Benzinga.com

Arista Networks Inc (NYSE: ANET) shares tanked in premarket trading on Friday, amid concerns around AI stocks trading at a premium. Although ethernet could prevail in the AI era, the company is unlikely to be a big winner of this trend, according to Rosenblatt Securities. The Arista Networks Analyst: Mike Genovese downgraded the rating for Arista Networks from Buy to Sell while slashing the price target from $330 to $210. The Arista Networks Thesis: The stock is trading at a significant premium, as investors see the ...Full story available on Benzinga.com

Applied Digital Corporation (NASDAQ: APLD) reported worse-than-expected third-quarter financial results on Thursday. Revenue of $43.3 million, up 208% Y/Y, missed the consensus of $51.9 million. Adjusted loss of 24 cents per share, missed the consensus for a loss of 10 cents per share, according to data from Benzinga Pro. Adjusted EBITDA loss came in at $(2.3) million compared to an adjusted EBITDA of $0.9 million in the prior year.  "During the quarter, Applied Digital encountered several challenges ...Full story available on Benzinga.com

Two of America's biggest companies, which have made "massive" bets on China, Tesla Inc. (NASDAQ:TSLA) and Apple Inc. (NASDAQ:AAPL), cannot abandon the country just because they're undergoing a "white-knuckle" period, says top analyst Dan Ives. What Happened: Tesla and Apple are both currently experiencing the impact of an economic slowdown in China and growing competition from local players like Warren Buffett-backed BYD Company Ltd. and Huawei Technologies. "China is the heart and lungs of Tesla's growth story. That's 35% to 40% demand that's [coming] from China," Ives said in an interview with Hankyung Global Market. While Tesla has seen a sliver of hope when it comes to sales of its vehicles made in China, Apple's sales in the country fell 33% year-on-year in February. Subscribe to the Benzinga Tech Trends newsletter to get all the latest tech developments delivered to your inbox. Apple, in particular, has been a victim of a larger geopolitical ...Full story available on Benzinga.com